Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive pathogens. The disposition of oritavancin in skin structures was investigated using a cantharide-indu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fetterly, Gerald J., Ong, Christine M., Bhavnani, Sujata M., Loutit, Jeffrey S., Porter, Steven B., Morello, Lisa G., Ambrose, Paul G., Nicolau, David P.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2005
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC538852/
https://ncbi.nlm.nih.gov/pubmed/15616289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.1.148-152.2005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars